Addex Therapeutics Ltd (SWX:ADXN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 7.14M |
| Revenue (ttm) | 167.29K |
| Net Income (ttm) | -6.05M |
| Shares Out | 111.25M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 417,877 |
| Average Volume | 357,815 |
| Open | 0.0646 |
| Previous Close | 0.0642 |
| Day's Range | 0.0574 - 0.0652 |
| 52-Week Range | 0.0472 - 0.1095 |
| Beta | 1.77 |
| RSI | 55.59 |
| Earnings Date | Nov 10, 2025 |
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG... [Read more]
Financial Performance
Financial StatementsNews
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Q2 2025 Addex Therapeutics Ltd Earnings Call Transcript
Q2 2025 Addex Therapeutics Ltd Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN) Q2 2025 Earnings Call October 1, 2025 10:00 AM EDTCompany ParticipantsTimothy Dyer - Co-Founder, CEO &...
Earnings Scheduled For September 30, 2025
Companies Reporting Before The Bell • Addex Therapeutics (NASDAQ: ADXN) is projected to report earnings for its second quarter. • Paychex (NASDAQ: PAYX) is estimated to report quarterly earnings at ...
Addex Therapeutics GAAP EPS of -CHF 0.02, income of CHF 0.04M
Addex Therapeutics Slips To Q2 Net Loss With Lower Income
(RTTNews) - Addex Therapeutics (ADXN) Tuesday reported a net loss in its second quarter, compared to a profit last year led by sharp decrease in income. On a continuing operations basis, net loss wide...
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 In...
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulat...
Addex Appoints Bank of New York Mellon as Depositary Bank
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portf...
Why Adobe Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket
Shares of Adobe Inc. (NASDAQ: ADBE) rose sharply in pre-market trading after the company posted better-than-expected third-quarter results and raised its fiscal 2025 outlook after Thursday's closing ...
Earnings Scheduled For September 1, 2025
Companies Reporting Before The Bell • Addex Therapeutics (NASDAQ: ADXN) is expected to report ... Full story available on Benzinga.com
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a...
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel s...
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulati...
Earnings Scheduled For June 19, 2025
Companies Reporting Before The Bell • 111 (NASDAQ: YI) is likely to report earnings for its first quarter. • Addex Therapeutics (NASDAQ: Full story available on Benzinga.com
Addex Therapeutics GAAP EPS of -CHF 0.01, income of CHF 0.07M
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, A...
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators f...
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a port...
Addex Convenes Annual General Meeting 2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric mod...
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of no...
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...
Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript
Addex Therapeutics reports FY results
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for devel...